B7-H3 Antibody (C-1): sc-398323

B7-H3 Antibody (C-1) is a mouse monoclonal IgG2b antibody that detects B7-H3 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). B7-H3, also known as B7-homolog 3 or B7RP-2, is a member of the B7 immunoglobulin superfamily and plays a crucial role in the regulation of T cell activation and immune responses. B7-H3 is widely expressed in non-lymphoid tissues and binds to a putative receptor on activated T cells that is distinct from other well-characterized receptors such as CD28, CTLA-4, ICOS, and PD-1. B7-H3 interactions with T cells promote the proliferation of both CD4+ and CD8+ T cells and suggest potential involvement in enhancing Th1 and cytotoxic T cell responses, which may contribute to antitumor activity. B7-H3′s ability to modulate cell-mediated immune responses against cancer positions B7-H3 as a promising candidate for therapeutic applications in oncology. With versatile applications and significant biological implications, anti-B7-H3 antibody (C-1) serves as an essential tool for researchers investigating immune regulation and cancer immunotherapy.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

B7-H3 Antibody (C-1) References:

1. Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity.  |  Loo, D., et al. 2012. Clin Cancer Res. 18: 3834-45. PMID: 22615450
2. B7-H3 promotes colorectal cancer angiogenesis through activating the NF-κB pathway to induce VEGFA expression.  |  Wang, R., et al. 2020. Cell Death Dis. 11: 55. PMID: 31974361
3. Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer.  |  Scribner, JA., et al. 2020. Mol Cancer Ther. 19: 2235-2244. PMID: 32967924
4. The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models.  |  Kendsersky, NM., et al. 2021. Clin Cancer Res. 27: 2938-2946. PMID: 33619171
5. B7-H3 Suppresses Antitumor Immunity via the CCL2-CCR2-M2 Macrophage Axis and Contributes to Ovarian Cancer Progression.  |  Miyamoto, T., et al. 2022. Cancer Immunol Res. 10: 56-69. PMID: 34799346
6. Engineering MMP-2 Activated Nanoparticles Carrying B7-H3 Bispecific Antibodies for Ferroptosis-Enhanced Glioblastoma Immunotherapy.  |  Fan, R., et al. 2023. ACS Nano. 17: 9126-9139. PMID: 37097811
7. Camel nanobody-based B7-H3 CAR-T cells show high efficacy against large solid tumours.  |  Li, D., et al. 2023. Nat Commun. 14: 5920. PMID: 37739951
8. Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma.  |  Brignole, C., et al. 2023. J Immunother Cancer. 11: PMID: 37775116
9. Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer.  |  Yamada, Y., et al. 2023. Sci Transl Med. 15: eadf6732. PMID: 37967200
10. New Emerging Targets in Cancer Immunotherapy: The Role of B7-H3.  |  Koumprentziotis, IA., et al. 2024. Vaccines (Basel). 12: PMID: 38250867

The preferred B7-H3 antibody is B7-H3 Antibody (F-11): sc-376769.